Recombinant Anti-AACT antibody [EPR5905] (ab129194)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR5905] to AACT
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-AACT antibody [EPR5905]
See all AACT primary antibodies -
Description
Rabbit monoclonal [EPR5905] to AACT -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P -
Species reactivity
Reacts with: Human -
Immunogen
Recombinant fragment within Human AACT aa 250-450. The exact sequence is proprietary.
-
Positive control
- WB: Human plasma and colon cancer lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR5905 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab129194 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/10000 - 1/50000. Detects a band of approximately 68 kDa (predicted molecular weight: 47 kDa).
|
Notes |
---|
WB
1/10000 - 1/50000. Detects a band of approximately 68 kDa (predicted molecular weight: 47 kDa). |
Target
-
Function
Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2. -
Tissue specificity
Plasma. Synthesized in the liver. Like the related alpha-1-antitrypsin, its concentration increases in the acute phase of inflammation or infection. Found in the amyloid plaques from the hippocampus of Alzheimer disease brains. -
Involvement in disease
Defects in SERPINA3 may be a cause of chronic obstructive pulmonary disease (COPD) [MIM:107280]. -
Sequence similarities
Belongs to the serpin family. -
Domain
The reactive center loop (RCL) extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site within the RCL, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 12 Human
- Omim: 107280 Human
- SwissProt: P01011 Human
- Unigene: 534293 Human
- Unigene: 710488 Human
-
Alternative names
- SERPINA3 antibody
- AACT antibody
- AACT_HUMAN antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab129194 has been referenced in 1 publication.
- Valko PO et al. In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study. J Sleep Res N/A:e12721 (2018). PubMed: 29961995